Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
López Cárdenes C M, Merino Sánchez-Cañete A, Vicente Santamaría S, Gascón Galindo C, Merino Sanz N, Tabares González A, Blitz Castro E, Morales Tirado A, Garriga García M, López Rozas M, Ramos Riesgo T, Álvarez Beltrán M, Gutiérrez Martínez J R, Suárez González M, García Romero R, De la Mano Hernández A, Muñoz Codoceo M R, Martín Fernández C, Tutau Gómez C, Torcuato Rubio E, Ortiz Pérez P, Loverdos Eseverri I, García Volpe C, Salcedo Lobato E, Martín Rivada A, Castro Millan A M, Del Brio Castillo R, Sierra San Nicolás S, Murray Hurtado M, Crehuá Gaudiza E, Medina Martínez M, González Jiménez D, y grupo de trabajo de FQ y páncreas de la SEGHNP
Аннотация
METHODS: We compared anthropometric parameters and body composition before and after 6 and 12 months of CFTRm treatment. Results are stratified into subgroups according to the modulator used with dual therapy with lumacaftor + ivacaftor or tezacaftor + ivacaftor (LUMA/TEZ + IVA) or triple therapy with elexacaftor + tezacaftor + ivacaftor (ELE + TEZ + IVA). Body composition data are available in patients treated with ELE + TEZ + IVA.
RESULTS: Two hundred and thirty-four children (55.1% male) were recruited. The median age was 13.6 years (inter-quartile range [IQR] 10.7-16.1). We can observe a statistically significant increase in the weight Z score and BMI Z score after CFTRm. In terms of changes in body composition, we observe a significant increase in fat mass (FM) expressed both in kilograms and as a percentage at 6 months (p < .05; Wilcoxon-test), with no such differences found at 12 months. We also observe a statistically significant increase in fat-free-mass (FFM), expressed in kilograms at 6 and 12 months (p < .05; Wilcoxon-test).
CONCLUSION: Weight status improved and changes in body composition occurred in children after CFTRm therapy, including an increase of fat mass. Further studies are needed to confirm these changes in body composition and their impact on disease progression.